Regulation of the Procoagulant Response to Arterial Injury

1999 ◽  
Vol 82 (08) ◽  
pp. 801-805 ◽  
Author(s):  
Peter Giesen ◽  
Alison Schecter ◽  
Yale Nemerson ◽  
Mark Taubman

IntroductionThrombosis is commonly associated with arterial injury. Clinically, this is seen with all interventional procedures designed to treat coronary artery stenosis, such as percutaneous transluminal coronary angioplasty (PTCA),1 directional coronary, 1 atherectomy (DCA)2 and coronary artery stenting.3 Acute thrombosis occasionally results in total occlusion of the vessel lumen. However, more typical is the deposition of smaller nonocclusive mural thrombi.Thrombosis is also a common feature of many animal models of arterial injury.4-8 These models have provided considerable information about the molecular events associated with injury-induced thrombus formation. Platelet adherence to the injured arterial wall occurs within minutes in all models of arterial injury. In some models, platelet deposition is followed by fibrin deposition, a consequence of activation of the coagulation cascade. The presence and extent of fibrin deposition varies with the degree of injury (superficial or deep), the type of vessel (carotid, femoral, aorta, or coronary), the state of the vessel prior to injury (normal, cholesterol fed, previously injured), and the species. In the pig carotid balloon injury model, endothelial denudation in the absence of medial injury is associated with platelet deposition but no fibrin generation. More severe injury, defined by the presence of a medial tear, results in marked platelet accumulation and fibrin generation, even in the presence of high doses of heparin.4,9 Unlike the porcine model, balloon injury to normal rodent arteries is associated with rapid platelet deposition but does not result in significant fibrin deposition, even in the presence of medial injury.5-8 In contrast to that found using normal arteries, fibrin deposition is seen when previously injured rabbit arteries, possessing a neointima, are subjected to a second injury.5,7,8,10 As determined by scanning and transmission electron microscopy, abundant fibrin formation is detected within 30 minutes of the reinjury. Platelet deposition is also more dense after the second injury and associated with fibrin-platelet microthrombi. We have recently found a similar difference between single and double injury in rat aorta and carotid arteries. These studies suggest that, in contrast to the deposition of platelets, which accompanies any injury to the arterial wall, the deposition of fibrin and the formation of large thrombi are more dependent on the type of injury produced and may be regulated by specific processes occurring in the arterial wall.

2001 ◽  
Vol 42 (3) ◽  
pp. 365-369 ◽  
Author(s):  
Shinobu Hosokawa ◽  
Yoshikazu Hiasa ◽  
Hiroshi Miyamoto ◽  
Naoki Suzuki ◽  
Takefumi Takahashi ◽  
...  

1998 ◽  
Vol 79 (01) ◽  
pp. 162-168 ◽  
Author(s):  
J. P. Bossavy ◽  
K. S. Sakariassen ◽  
A. Barret ◽  
B. Boneu ◽  
Y. Cadroy

SummaryNo quantitative, simple and non-radioactive method has been described for measuring the platelet content of experimental thrombi. The aim of the present study was to develop a simple method for quantifying platelets in thrombi formed on thrombogenic surfaces in flowing native human blood. To test the relevance of this new method, the effect of unfractionated heparin on arterial thrombus formation was investigated. Tissue factor (TF)- and collagen-coated coverslips were exposed to non-anticoagulated blood at an arterial wall shear rate (2,600 s–1) for 1 to 4 min. Platelet deposition was quantified by measuring the P-selectin (PS) and β-thromboglobulin (βTG) content of dissolved plasmin-digested thrombi using immunoenzymoassays; fibrin deposition was determined by measuring the D-dimer levels. These results were compared to those established by morphometrical analysis.Morphometric evaluation showed that fibrin deposition was maximum on TF by 1 min perfusion time. Platelets deposited subsequently and reached a maximum at 3 min. On collagen, platelets deposited directly on the collagen fibrils without detectable fibrin deposit. Platelet deposition increased from 1 to 4 min. Platelet deposition quantified by PS was correlated to the values obtained by morphometry (r = 0.72, r = 0.67, p <0.001, on TF and collagen, respectively). As compared to PS, βTG measurements gave an underestimation of the size of the thrombus platelet number. Unfractionated heparin infused through a mixing device proximal to the perfusion chamber to obtain plasma concentrations of 0.5, 1 and 3 IU/ml, reduced fibrin deposition on TF-coated coverslips in a dose-dependent manner (77% reduction at 3 IU/ml, p <0.01), but had no significant effect on platelet deposition (33% at 3 IU/ml, p >0.05). In contrast, heparin had no effect on fibrin or platelet deposition on collagen-coated coverslips.Thus, a new quantitative and simple method for measuring platelet deposition in flowing blood has been developed and characterized. Utilizing this system, we have demonstrated that unfractionated heparin did not inhibit arterial thrombus formation either on procoagulant or on proaggregant surface.


2002 ◽  
Vol 87 (04) ◽  
pp. 748-755 ◽  
Author(s):  
Marina Camera ◽  
Vincenzo Toschi ◽  
Carmen Comparato ◽  
Roberta Baetta ◽  
Francesca Rossi ◽  
...  

SummaryHigh cholesterol levels are a known risk factor for coronary events. The molecular links between high serum cholesterol and the increased thrombogenicity of the arterial wall are still matter of investigation. In the present study we investigate the relationship between plasma cholesterol, thrombus formation and TF expression in a atherosclerotic rabbit model.Hypercholesterolemic rabbits showed a pronounced TF staining as well as NF-κB activation in the aortic arch. A consistent vessel wall platelet deposition was also observed. Treatment with fluvastatin reduced lipid accumulation, TF overexpression (-60%), NF-κB activation, and platelet deposition (-56%). In vitro studies showed that the drug upregulated IκBa in unstimulated as well as in TNFa-stimulated cells and also impaired the TNF-α-induced Cdc42 prenylation, indicating that fluvastatin interferes with the transcriptional activation of TF gene.These results indicate that the prothrombotic phenotype of arterial wall, associated with elevated serum cholesterol levels, is mediated by TF overexpression. Fluvastatin treatment reduces the prothrombotic tendency by inhibiting TF synthesis.


1977 ◽  
Author(s):  
G. D. Wilner ◽  
W. J. Casarella ◽  
C. Fenoglio ◽  
R. E. Baier

The use of fibrinopeptide A (FPA) levels to assess the hemostatic biocompatibility of prosthetic devices has been evaluated. Commercial angiographic catheters (7 French) of 5 different materials were introduced percutaneously 10 cm retrograde into the femoral arteries of anesthetized mongrel dogs. Catheter lumens were continually flushed with saline (1 ml/min). At intervals over a 30 minute period, saline flow was stopped and blood samples were withdrawn through the catheter lumen for FPA assay. Clot formation in catheter lumens was evaluated by scanning electron microscopy (SEM). The catheters could be divided into three groups based on FPA level generated and deposition of fibrin and platelets in the lumen. Group I (the PERT catheter) caused no increase in FPA (mean level 0.5 pmol/ml, equal to the level in the absence of any catheter), no fibrin deposition, and moderate platelet deposition. Group II (Torcon and Teflon catheters) caused moderate FPA generation (mean 7.1 pmol/ml), moderate fibrin deposition, and moderate platelet deposition. Group III catheters (polyurethane and Dacron) caused marked FPA generation (mean 26.2 pmol/ml), marked fibrin deposition, but variable platelet deposition. Thus mean FPA levels over the 30 minute experimental period correlated well with intraluminal fibrin deposition; FPA measurements should be useful in assessing the degree to which different catheters stimulate fibrin formation. FPA levels did not correlate with intraluminal platelet deposition and thus will not reflect platelet contributions to thrombus formation.


2012 ◽  
Vol 107 (06) ◽  
pp. 1141-1150 ◽  
Author(s):  
J. Eileen Bird ◽  
Patricia Smith ◽  
Xinkang Wang ◽  
William Schumacher ◽  
Frank Barbera ◽  
...  

SummaryPlasma kallikrein is a multifunctional serine protease involved in contact activation of coagulation. Deficiency in humans is characterised by prolonged activated partial thromboplastin time (aPTT); however, the balance between thrombosis and haemostasis is not fully understood. A study of plasma kallikrein-deficient mice revealed increased aPTT, without prolonged bleeding time. Prekallikrein antisense oligonucleotide (ASO) treatment in mice suggested potential for a positive therapeutic index. The current goal was to further define the role of plasma kallikrein in coagulation. Blood pressure and heart rate were normal in plasma kallikrein-deficient mice, and mice were completely protected from occlusion (100 ± 1.3% control flow) in 3.5% FeCl3 -induced arterial thrombosis versus heterozygotes (20 ± 11.4%) and wild-type littermates (8 ± 0%). Vessels occluded in 8/8 wild-type, 7/8 heterozygotes, and 0/8 knockouts. Anti-thrombotic protection was less pronounced in 5% FeCl3-induced arterial injury. Integrated blood flow was 8 ± 0% control in wild-type and heterozygotes, and significantly (p<0.01) improved to 43 ± 14.2% in knockouts. The number of vessels occluded was similar in all genotypes. Thrombus weight was significantly reduced in knockouts (−47%) and heterozygotes (−23%) versus wild-type in oxidative venous thrombosis. Average tail bleeding time increased modestly in knockout mice compared to wild-type. Average renal bleeding times were similar in all genotypes. These studies confirm and extend studies with prekallikrein ASO, and demonstrate that plasma kallikrein deletion prevents occlusive thrombus formation in mice with a minimal role in provoked bleeding. Additional support for the significance of the intrinsic pathway in the coagulation cascade is provided, as well as for a potential new anti-thrombotic approach.


2019 ◽  
Vol 21 (6) ◽  
pp. 673-682 ◽  
Author(s):  
Jack P M Andrews ◽  
Christophe Portal ◽  
Tashfeen Walton ◽  
Mark G Macaskill ◽  
Patrick W F Hadoke ◽  
...  

Abstract Aims Cardiovascular thrombosis is responsible a quarter of deaths annually worldwide. Current imaging methods for cardiovascular thrombosis focus on anatomical identification of thrombus but cannot determine thrombus age or activity. Molecular imaging techniques hold promise for identification and quantification of thrombosis in vivo. Our objective was to assess a novel optical and positron-emitting probe targeting Factor XIIIa (ENC2015) as biomarker of active thrombus formation. Methods and results Optical and positron-emitting ENC2015 probes were assessed ex vivo using blood drawn from human volunteers and passed through perfusion chambers containing denuded porcine aorta as a model of arterial injury. Specificity of ENC2015 was established with co-infusion of a factor XIIIa inhibitor. In vivo18F-ENC2015 biodistribution, kinetics, radiometabolism, and thrombus binding were characterized in rats. Both Cy5 and fluorine-18 labelled ENC2015 rapidly and specifically bound to thrombi. Thrombus uptake was inhibited by a factor XIIIa inhibitor. 18F-ENC2015 remained unmetabolized over 8 h when incubated in ex vivo human blood. In vivo, 42% of parent radiotracer remained in blood 60 min post-administration. Biodistribution studies demonstrated rapid clearance from tissues with elimination via the urinary system. In vivo,18F-ENC2015 uptake was markedly increased in the thrombosed carotid artery compared to the contralateral patent artery (mean standard uptake value ratio of 2.40 vs. 0.74, P &lt; 0.0001). Conclusion  ENC2015 rapidly and selectively binds to acute thrombus in both an ex vivo human translational model and an in vivo rodent model of arterial thrombosis. This probe holds promise for the non-invasive identification of thrombus formation in cardiovascular disease.


2000 ◽  
Vol 83 (03) ◽  
pp. 496-502 ◽  
Author(s):  
Anthony Gershlick ◽  
Kai Hogrefe ◽  
Julia Baron ◽  
Thomas Johnston ◽  
Amanda Hussey ◽  
...  

SummaryIn high-risk and complicated coronary intervention, the risk of acute closure is unpredictable. Thrombus and platelet deposition at the intervention site may also have further effects on subsequent restenosis. In vivo infusion of activated protein C has previously been shown to achieve potent anticoagulation without any haemostatic side effects. We now evaluated the in vitro and in vivo efficacy of polymer-coated coronary stents loaded with purified rabbit Activated Protein C (APC). By measuring 125I-fibrinogen/fibrin deposition APC-loaded stent-wires were antithrombotic compared to albumin-loaded, inhibited-APCloaded, plain polymer-coated and stainless steel stent-wires. In a balloon injury rabbit iliac artery model, APC-loaded stents did not occlude (0/14) compared to plain stents (9/15) and BSA-loaded stents (2/4). Relative 111In-labelled platelet deposition showed a similarly significant degree of inhibition. In conclusion, APC-loading could render stents significantly less thrombotic. Whether an effective antithrombogenic stent like this effectively reduces restenosis rates warrants further evaluation.


1995 ◽  
Vol 73 (03) ◽  
pp. 535-542 ◽  
Author(s):  
N Crawford ◽  
A Chajara ◽  
G Pfliegler ◽  
B EI Gamal ◽  
L Brewer ◽  
...  

SummaryDrugs can be electro-encapsulated within platelets and targeted to damaged blood vessels by exploiting the platelet’s natural haemostatic properties to adhere to collagen and other vessel wall constituents revealed by injury. A rat aorta balloon angioplasty model has been used to study the effect on platelet deposition of giving iloprost loaded platelets i.v. during the balloon injury. After labelling the circulating platelets with 111-Indium before balloon injury, time course studies showed maximum platelet deposition on the injured aorta occurred at about 1 h post-injury and the deposition remained stable over the next 2-3 h. When iloprost-loaded platelets were given i.v. during injury and the circulating platelet pool labelled with 111-Indium 30 min later, platelet deposition, measured at 2 h postinjury, was substantially and significantly reduced compared with control platelet treatment. Some antiproliferative effects of iloprost-loaded platelets given i.v. during injury have also been observed. Whereas the incorporation of [3H]-thymidine into aorta intima-media DNA at 3 days post injury was 62-fold higher in balloon injured rats than in control sham operated rats, thymidine incorporation into intima/media of rats which had received iloprost loaded platelets during injury was reduced as compared with rats subjected only to the injury procedure. The reduction was only of near significance, however, but at 14 days after injury the total DNA content of the aorta intima/media of rats given iloprost loaded platelets during injury was significantly reduced. Although iloprost loaded platelets can clearly inhibit excessive platelet deposition, other encapsulated agents may have greater anti-proliferative effects. These studies have shown that drug loaded platelets can be targeted to injured arteries, where they may be retained as depots for local release. We believe this novel drug delivery protocol may have therapeutic potential in reducing the incidence of occlusion and restenosis after angioplasty and thrombolysis treatment. Electro-encapsulation of drugs into platelets is a simple procedure and, using autologous and fully biocompatible and biodegradable platelets as delivery vehicles, might overcome some of the immunological and toxicological problems which have been encountered with other delivery vectors such as liposomes, microbeads, synthetic microcapsules and antibodies.


1997 ◽  
Vol 78 (05) ◽  
pp. 1408-1414 ◽  
Author(s):  
Frank Roesken ◽  
Martin Ruecker ◽  
Brigitte Vollmar ◽  
Nicole Boeckel ◽  
Eberhard Morgenstern ◽  
...  

SummaryThe alteration of rheological blood properties as well as deterioration of vascular perfusion conditions and cell-cell interactions are major determinants of thrombus formation. Herein, we present an experimental model which allows for quantitative in vivo microscopic analysis of these determinants during both thrombus formation and vascular recanalisation. The model does not require surgical preparation procedures, and enables for repeated analysis of identical microvessels over time periods of days or months, respectively. After i.v. administration of FITC-dextran thrombus formation was induced photochemically by light exposure to individual arterioles and venules of the ear of ten anaesthetised hairless mice. In venules, epiillumination induced rapid thrombus formation with first platelet deposition after 0.59 ± 0.04 min and complete vessel occlusion within 7.48 ±1.31 min. After a 24-h time period, 75% of the thrombosed venules were found recanalised. Marked leukocyte-endothelial cell interaction in those venules indicated persistent endothelial cell activation and/or injury, even after an observation period of 7 days. In arterioles, epi-illumination provoked vasomotion, while thrombus formation was significantly (p <0.05) delayed with first platelet deposition after 2.32 ± 0.22 min and complete vessel occlusion within 20.07 ±3.84 min. Strikingly, only one of the investigated arterioles was found recanalised after 24 h, which, however, did not show leukocyte-endothelial cell interaction. Heparin (300 U/kg, i.v.) effectively counteracted the process of thrombus formation in this model, including both first platelet deposition and vessel occlusion. We conclude that the model of the ear of the hairless mouse allows for distinct in vivo analysis of arteriolar and venular thrombus formation/ recanalisation, and, thus, represents an interesting tool for the study of novel antithrombotic and thrombolytic strategies, respectively.


1985 ◽  
Vol 53 (03) ◽  
pp. 423-427 ◽  
Author(s):  
Stephen R Hanson ◽  
Laurence A Harker

SummarySuloctidil has been evaluated in the baboon for its antithrombotic efficacy using models of both acute and chronic arterial thrombogenesis. Acute thrombus formation was initiated by Dacron vascular grafts inserted as extension segments into chronic arteriovenous shunts. 111In-platelet deposition was measured by scintillation camera imaging for one hour. The results after oral administration of suloctidil (100 mg/kg/d in two divided doses) were not different from control studies. Moreover, concurrent heparin anticoagulation did not affect 111In-platelet deposition compared with control data. In contrast, ticlopidine (20 mg/ kg/d) significantly decreased platelet deposition that was reduced further by the addition of heparin.Chronic arterial-thromboembolism was initiated by segments of polyurethane (Biomer) cannula introduced into chronic arteriovenous shunts. Thrombus formation by the polyurethane cannula was measured as 111In-platelet turnover (corrected for removal of senescent platelets). Cannula platelet consumption was unaffected by suloctidil (20 mg/kg/d given in two divided doses for two days preceding and throughout the period of platelet survival measurement). In contrast, dipyridamole (10 mg/ kg/d) and sulfinpyrazone (100 mg/kg/d) completely interrupted cannula platelet consumption.We conclude that suloctidil probably has little or no effect on platelet-dependent thrombus formation.


Sign in / Sign up

Export Citation Format

Share Document